StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
September 29, 2026 5:14 AM
Stifel analyst Dara Azar reiterated a Buy rating and $38.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
